Ozarelix

Summary

Ozarelix is an investigational decapeptide that acts as a gonadotropin‑releasing hormone (GnRH) antagonist. Developed for subcutaneous administration, it is being explored for its ability to block GnRH receptors and thereby suppress downstream reproductive hormone signaling. Current research focuses on its physicochemical properties, especially its strong binding to anionic polymers and propensity to form nanostructured aggregates that could be harnessed for drug‑delivery applications.

Mechanism of Action

As a GnRH antagonist, ozarelix competitively binds to the GnRH receptor on pituitary gonadotroph cells, preventing the natural hormone from activating the receptor. This blockade inhibits the release of luteinising hormone (LH) and follicle‑stimulating hormone (FSH), disrupting the hormonal cascade that regulates gonadal function. The peptide’s decapeptide structure enables high‑affinity receptor interaction typical of GnRH antagonists.

What the Research Shows

Laboratory studies have shown that ozarelix, a cationic decapeptide, forms strong electrostatic complexes with a range of anionic polyelectrolytes such as hyaluronate, carboxymethylcellulose, xanthan, alginate and others, with binding constants on the order of 10^6 M⁻¹. These interactions generate nanofibers of 4–25 nm diameter and up to several micrometres in length, whose morphology depends on the partner polymer. Spectroscopic analyses reveal conformational changes driven by aromatic side‑chain interactions. Fluorescence assays determined a critical aggregation concentration, indicating a propensity to self‑assemble. Recent 1H‑NMR and all‑atom molecular‑dynamics work ranked ozarelix among peptides with high aggregation propensity and identified acetate counter‑ions within its aggregates. Clinical‑trial databases list ozarelix as an investigational agent, but no efficacy or safety data have been published.

Reported Benefits

The peptide’s high affinity for anionic polymers and ability to form stable nanofibrous networks suggest it could be employed to create sustained‑release formulations or hydrogel‑based delivery systems. Its strong binding may prolong local residence time after subcutaneous injection, potentially reducing dosing frequency. Additionally, the well‑characterised aggregation behaviour provides a platform for rational formulation design.

Limitations of the Evidence

All reported data are limited to in‑vitro, biophysical, or computational studies; no pre‑clinical or clinical efficacy outcomes are available. The strong aggregation tendency, while useful for delivery, may also pose formulation challenges such as precipitation or inconsistent dosing. Ozarelix remains investigational with no regulatory approval, and its pharmacodynamic and pharmacokinetic profiles in humans are unknown.

Safety Considerations

The abstracts provide no information on adverse effects, toxicity, or tolerability. Consequently, the safety profile of ozarelix in humans is currently undefined. Its investigational status means that any clinical use would be confined to controlled research settings, and potential immunogenicity or off‑target effects have not been evaluated.

How It Is Administered

Ozarelix is listed for subcutaneous administration. In research settings it is typically formulated as an aqueous peptide solution for injection, often combined with anionic polymers to explore nanofiber‑based delivery systems. No commercial dosage forms or devices are described.

Routes of Administration

Goals & Uses

• Prostate cancer androgen deprivationOncologyModerate
• Reduction of lower urinary tract symptoms (LUTS)UrologyLow
• Testosterone suppression without flareEndocrinologyModerate
• Benign prostatic hyperplasia (BPH) symptom reliefUrologyModerate

Contraindications

• Severe hepatic impairmentOrganModerateLiver function concerns
• PregnancyPopulationHighPotential fetal risk or insufficient safety data
• Hypersensitivity to GnRH analoguesAllergy/ImmunologyHigh

Adverse Effects

• QT interval prolongationCardiacUncommon
• Injection site reactionsLocalCommon
• Hot flashesEndocrine / VasomotorCommon
• FatigueGeneralCommonLow energy or tiredness
• Erectile dysfunctionSexual/ReproductiveCommon
• Bone mineral density reductionMusculoskeletalUncommon

Drug Interactions

• Anticoagulants (e.g., warfarin)Low
• QT-prolonging agents (e.g., antiarrhythmics, antipsychotics)Moderate

Population Constraints

• Pediatric patientsAgeAbsolute
• Females of reproductive potentialReproductiveRelative
• Patients with osteoporosisMusculoskeletalRelative
• Patients with pre-existing cardiovascular diseaseCardiovascularRelative

Regulatory Status

• European UnionInvestigationalNo EMA marketing authorization; evaluated in European clinical trials for prostate cancer and BPH.
• United StatesInvestigationalStudied in Phase II clinical trials; no FDA approval obtained. Development appears stalled.
• United KingdomInvestigationalNo MHRA approval; remains an investigational compound.

Ozarelix has not received FDA, EMA, or other major regulatory approval. It was studied in Phase II clinical trials for prostate cancer and BPH but development has not progressed to Phase III or approval as of available data.

Evidence & Sources

• The impact of polyelectrolyte structure on the shape of nanoassemblies with cationic peptides
  Journal ArticleLowFerstl M, et al.2013-01-01T00:00:00.000000Z
• Nanofibers resulting from cooperative electrostatic and hydrophobic interactions between peptides and polyelectrolytes of opposite charge
  Journal ArticleLowFerstl M, et al.2011-01-01T00:00:00.000000Z
• Gateways to clinical trials
  Journal ArticleLowBayes M, Rabasseda X, Prous JR2007-01-01T00:00:00.000000Z
• Fluorescence spectroscopic determination of the critical aggregation concentration of the GnRH antagonists Cetrorelix, Teverelix and Ozarelix
  Journal ArticleLowSchneider A, Lang A, Naumann W2010-01-01T00:00:00.000000Z
• Gateways to clinical trials
  Journal ArticleLowBayés M, Rabasseda X, Prous JR2007-01-01T00:00:00.000000Z
• Aggregation Behavior of Structurally Similar Therapeutic Peptides Investigated by (1)H NMR and All-Atom Molecular Dynamics Simulations
  Journal ArticleLowHjalte J, et al.2022-01-01T00:00:00.000000Z

Frequently Asked Questions